Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

A Phase 1b Study of Aurora A Kinase Inhibitor LY3295668 erbumine in Monotherapy and Combination Therapy in Patients with Metastatic Breast Cancer post CDK4/6 Inhibitor and Endocrine Therapy

Not Enrolling

Trial ID:NCT03955939

View complete trial on

Protocol #:19-314

877-DF-TRIAL (877-338-7425)

Condition(s):Metastatic Breast Cancer


Principal Investigator:Tolaney, Sara, M

Site Investigator(s):Wander, Seth, A.

Site Research Nurse(s):Selland, Britt,

Trial Description:
The reason for this study is to determine the recommended phase 2 dose of the study drug LY3295668 erbumine in participants with breast cancer that has spread to other parts of the body.

Eligibility Requirements:
- Participant must have hormone receptor positive and HER2 negative metastatic breast cancer
- Participant must have progressed on at least 1 line of endocrine therapy and 1 cyclin dependent kinase (CDK)4/6 inhibitor
- Participant must be able and willing to undergo mandatory tumor biopsy
- Participant must have normal organ function
- Participant must be able to swallow capsules
Exclusion Criteria:
- Participant must not have had prior chemotherapy for mBC. Chemotherapy in the adjuvant/neoadjuvant setting is permitted
- Participant must not be currently enrolled in a clinical study
- Participant must not have another serious medical condition
- Participant must not have previously received an aurora kinase inhibitor

Protocol #: 19-314

Questions & Enrollment